HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1850902TKNO stock profile & AI dashboard →

13F Pro Quality Score

26.6/100

Rank #2,613 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

48.2/100

Profitability

13.1/100

Balance Sheet

12.7/100

Earnings Quality

37.6/100

Free Cash Flow

13.8/100

Institutional Flow

54.5/100

Revenue Scale

7.8/100

Dilution Risk

18.1/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

TKNO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Alpha Teknova, Inc. (TKNO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TKNO at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,613 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (7.8) and balance sheet strength (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Alpha Teknova, Inc. reports quarterly revenue of $12.2M, net income of $-3.2M, free cash flow of $-596.0K. Top institutional holders of TKNO by reported 13-F value include ROYCE & ASSOCIATES, VANGUARD CAPITAL MANAGEMENT, Roubaix Capital, based on the most recent SEC filings. TKNO trades on the Nasdaq exchange and files with the SEC under CIK 1850902. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TKNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alpha Teknova, Inc. directly from SEC EDGAR. Alpha Teknova, Inc.'s 13F Pro composite quality score has ranged between 12 and 35 since 2022, currently 26.6 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.

Fun facts about Alpha Teknova, Inc.

Quirks, history, and lore behind TKNO — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. life sciences company · small-cap · listed on Nasdaq · headquartered in California.
  • 2
    The Numbers
    Annual revenue in the range of tens of millions of dollars, serving a niche but critical corner of the biopharma supply chain — small by Wall Street standards, indispensable to its customers.
  • 3
    The History
    Founded in the 1990s, it spent decades as a quiet behind-the-scenes supplier before going public on Nasdaq in 2021, right as demand for its products was surging.
  • 4
    The Secret
    It doesn't make drugs — it makes the buffers, reagents, and culture media that biopharmaceutical labs need to develop and manufacture drugs; if you run a cell therapy program, you probably use its products.
  • 5
    The Lore
    Its facility in Hollister, California — a small agricultural town — is essentially a custom recipe shop for scientists, producing made-to-order biological solutions at scale.
  • 6
    The Giveaway
    The ticker spells out its mission pretty clearly: TKNO, short for a name blending "alpha" (the Greek symbol of excellence) with "teknova" — a biopharma reagent and buffer maker that keeps the world's drug labs stocked.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$12.2M

Net Income

Q2 2026

$-3.2M

Free Cash Flow

Q2 2026

$-596.0K

ROIC

Q2 2026

-15.3%

D/E Ratio

Q2 2026

0.21

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+7.4% YoY
$40.5MFY 2025
FY22 $41.4MFY23 $36.7MFY24 $37.7MFY25 $40.5M

Net Income

+35.5% YoY
$-17.3MFY 2025
FY22 $-47.5MFY23 $-36.8MFY24 $-26.7MFY25 $-17.3M

Operating Income

+35.1% YoY
$-17.0MFY 2025
FY22 $-49.7MFY23 $-35.6MFY24 $-26.1MFY25 $-17.0M

EPS (Diluted)

+43.9% YoY
$-0.32FY 2025
FY22 $-1.69FY23 $-1.16FY24 $-0.57FY25 $-0.32

Total Assets

-12.8% YoY
$103.6MFY 2025
FY22 $152.3MFY23 $128.6MFY24 $118.8MFY25 $103.6M

Total Debt

-2.7% YoY
$13.1MFY 2025
FY22 $22.0MFY23 $13.3MFY24 $13.5MFY25 $13.1M

Op. Cash Flow

+30.2% YoY
$-8.6MFY 2025
FY22 $-27.4MFY23 $-18.8MFY24 $-12.4MFY25 $-8.6M

Free Cash Flow

+27.5% YoY
$-9.8MFY 2025
FY22 $-55.5MFY23 $-26.7MFY24 $-13.5MFY25 $-9.8M

Get alerted when TKNO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alpha Teknova, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of TKNO

Companies Similar to TKNO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SI

SHOULDER INNOVATIONS, INC.

29
AI score
Similar quality profile · 2 shared holders
KIDS

ORTHOPEDIATRICS CORP

37
AI score
Similar quality profile · 2 shared holders
CYRX

Cryoport, Inc.

30
AI score
Similar quality profile · 2 shared holders
VNDA

Vanda Pharmaceuticals Inc.

27
AI score
Similar quality profile · 2 shared holders
JANX

Janux Therapeutics, Inc.

28
AI score
Similar quality profile · 3 shared holders
CRBU

Caribou Biosciences, Inc.

8
AI score
Similar quality profile · 3 shared holders
SDGR

Schrodinger, Inc.

30
AI score
Similar quality profile · 2 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put TKNO on your watchlist

Track score changes the day Alpha Teknova, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is TKNO a good stock to buy?

13F Pro's AI-powered analysis of Alpha Teknova, Inc. (TKNO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TKNO are available on the TKNO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TKNO is classified as a small company.

Which hedge funds own TKNO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TKNO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alpha Teknova, Inc.'s investment landscape.